Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while State Street SPDR S&P Homebuilders ETF trades at $94.77 (market cap $1.49B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 8.4× State Street SPDR S&P Homebuilders ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| HALO | XHB | |
|---|---|---|
Market Cap | $12.58B | $1.49B |
Volume | 2,179,278 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $115.22 | $121.36 |
52-Week Low | $61.63 | $94.77 |
Typical Hold Time | 1 Days | 33 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XHB (SPDR S&P Homebuilders ETF) trades at $95.66, up 0.81% with a bearish technical signal from moving averages. The ETF faces headwinds from rising mortgage rates above 7% but shows potential as homebuilder valuations signal historical buying opportunities. Recent housing data shows mixed signals with new home sales rising 1.6% in June while existing home sales declined 2.4%.
The ETF presents a contrarian opportunity as battered homebuilder stocks may rebound if housing affordability improves. Key risks include persistent high mortgage rates and economic uncertainty. Institutional activity shows mixed signals with Greenland Capital's $17.33 million investment contrasting CoreCap's 99.3% position reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
